NEW YORK, July 1, 2016 /PRNewswire/ --
On Thursday, June 30, 2016, the
NASDAQ Composite ended the trading session at 4,842.67, up 1.33%;
the Dow Jones Industrial Average advanced 1.33%, to finish at
17,929.99; and the S&P 500 closed at 2,098.86, up 1.36%. The
gains were broad based as all the sectors ended the session in
positive. Stock-Callers.com has initiated coverage on the following
equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery
Sciences International Inc. (NASDAQ: BDSI), Sequenom Inc. (NASDAQ:
SQNM), and INSYS Therapeutics Inc. (NASDAQ: INSY). Learn more about
these stocks by accessing their free trade alerts at:
http://stock-callers.com/registration
Cambridge, Massachusetts
headquartered biopharmaceutical Company, Genocea Biosciences Inc.'s
stock finished Thursday's session 7.24% lower at $4.10 with a total volume of 896,080 shares
traded. The stock is trading below its 50-day moving average by
2.50%. Genocea Biosciences' stock has a Relative Strength Index
(RSI) of 49.74. Sign up and read the free notes on GNCA at:
http://stock-callers.com/registration/?symbol=GNCA
Raleigh, North Carolina
headquartered specialty pharmaceutical Company, BioDelivery
Sciences International Inc.'s stock lost 2.88% to close the day at
$2.36 with a total volume of 913,362
shares traded. The Company's shares have gained 7.27% in the last
one month. The stock is trading 7.39% below its 50-day moving
average. Additionally, BioDelivery Sciences International's stock
has an RSI of 45.42. The complimentary notes on BDSI can be
downloaded in PDF format at:
http://stock-callers.com/registration/?symbol=BDSI
On Thursday, shares in San Diego,
California headquartered life sciences Company, Sequenom
Inc., ended the session 2.80% lower at $0.91 with a total volume of 724,098 shares
traded. The stock is trading 19.37% below its 50-day moving
average. Moreover, shares of Sequenom have an RSI of 34.71.
Register for free on Stock-Callers.com and access the latest
research on SQNM at:
http://stock-callers.com/registration/?symbol=SQNM
On Thursday, shares in Chandler,
Arizona headquartered INSYS Therapeutics Inc. ended the day
3.35% higher at $12.94 with a total
volume of 620,240 shares traded. The Company markets Subsys, a
sublingual fentanyl spray for breakthrough cancer pain in
opioid-tolerant cancer patients in the U.S. Shares of the Company
traded at a PE ratio of 18.57. The stock is trading below its
50-day moving average by 9.46%. Furthermore, shares of INSYS
Therapeutics have an RSI of 44.15. Get free access to your trade
alert on INSY at:
http://stock-callers.com/registration/?symbol=INSY
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA